Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis.
It has been reported that tuberculosis (TB) worsens after cessation of tumor necrosis factor-α inhibitors and starting anti-TB treatment. Little is known about the immunological pathogenesis of this paradoxical response (PR). We report the first case of a TB patient in whom PR occurred concurrently with elevation of circulating tumor necrosis factor-α (TNFα) levels. A 75-year-old woman, who had been treated with adalimumab for SAPHO syndrome, developed disseminated TB. Soon after administration of anti-TB treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol), and after discontinuation of adalimumab, a PR occurred. Serial testing of serum cytokine levels revealed a marked increase in TNFα, and a decline in interferon-γ levels. Despite intensive treatment with antibiotics, prednisolone, noradrenaline, and mechanical ventilation, acute respiratory distress syndrome developed and she died. Thus, overproduction of TNFα after cessation of TNFα inhibitors may partially account for the pathogenesis of a PR. This supports preventative or therapeutic reinitiation of TNFα inhibitors when PR occurs. Serial monitoring of circulating inflammatory cytokine levels could lead to earlier identification of a PR.
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Sho
S
Watanabe
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Yugo
Y
Kaneko
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Hironori
H
Kawamoto
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Tomoki
T
Maehara
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Yuri
Y
Baba
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Ikumi
I
Fujisaki
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Nayuta
N
Saito
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Kai
K
Ryu
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Aya
A
Seki
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Tsugumi
T
Horikiri
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Akira
A
Kinoshita
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Hiroshi
H
Takeda
Division of Respiratory Medicine, Department of Internal Medicine, Jikei Daisan Hospital, 11-1, Izumihoncho 4, Komae City, Tokyo, Japan.
Keisuke
K
Saito
Department of Respiratory Medicine, Jikei University School of Medicine, 19-18, Nishishinbashi 3, Minato-ku, Tokyo, Japan.
Kazuyosi
K
Kuwano
Adalimumab; ELISA, enzyme-linked immunosorbent assay; HRCT, high resolution computer tomography; IGRA, Interferon gamma release assay; IRIS, immune reconstruction syndrome; Immune reconstitution inflammatory syndrome; PR, Paradoxical response; Paradoxical response; TB, tuberculosis; TNF-α inhibitor; TNFα, Tumor necrosis factor alpha; Tuberculosis; Tumor necrosis factor alpha